Abstract
The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.
| Original language | English |
|---|---|
| Pages (from-to) | 55-60 |
| Number of pages | 6 |
| Journal | Cytotechnology |
| Volume | 55 |
| Issue number | 2-3 |
| DOIs | |
| Publication status | Published - Dec 1 2007 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cell Biology
- Biotechnology
- Clinical Biochemistry
Cite this
Recent advances in the generation of human monoclonal antibody. / Yamashita, Makiko; Katakura, Yoshinori; Shirahata, Sanetaka.
In: Cytotechnology, Vol. 55, No. 2-3, 01.12.2007, p. 55-60.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Recent advances in the generation of human monoclonal antibody
AU - Yamashita, Makiko
AU - Katakura, Yoshinori
AU - Shirahata, Sanetaka
PY - 2007/12/1
Y1 - 2007/12/1
N2 - The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.
AB - The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.
UR - http://www.scopus.com/inward/record.url?scp=36749080892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749080892&partnerID=8YFLogxK
U2 - 10.1007/s10616-007-9072-5
DO - 10.1007/s10616-007-9072-5
M3 - Review article
C2 - 19002994
AN - SCOPUS:36749080892
VL - 55
SP - 55
EP - 60
JO - Cytotechnology
JF - Cytotechnology
SN - 0920-9069
IS - 2-3
ER -